In our previous studies, Tat-SP4 showed moderate anti-proliferative efficacy in cell line models of non-small-cell lung cancer (NSCLC) and HER2+ breast cancer with IC50 values of ~30–50 μM [27,28]. Here, ERBB2 is linked to breast cancer.